Sio Gene Therapies Inc.

OTCPK:SIOX Voorraadrapport

Marktkapitalisatie: US$34.8m

Sio Gene Therapies Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

David Nassif

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO4.6yrs
Eigendom CEO0.06%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

Mar 04
Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

Nov 19
Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

Recent updates

Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?

Oct 19
Can Sio Gene Therapies (NASDAQ:SIOX) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

Jun 27
Here's Why We're A Bit Worried About Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

My Favorite Stock For 2022: Sio Gene Therapies

Dec 27

Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure

Oct 25

We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely

Sep 28
We're Hopeful That Sio Gene Therapies (NASDAQ:SIOX) Will Use Its Cash Wisely

Sio Gene Therapies EPS beats by $0.12

Jun 09

Sio Gene Therapies: Gene Therapies For Neurodegeneration

May 28

We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully

May 07
We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully

Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

Mar 04
Have Insiders Been Buying Sio Gene Therapies, Inc. (NASDAQ:SIOX) Shares?

Sio Gene Therapies secures $11.6M from sale of Arvelle Therapeutics

Feb 04

What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?

Jan 28
What Is The Ownership Structure Like For Sio Gene Therapies, Inc. (NASDAQ:SIOX)?

Sio Gene Therapies to sell Arvelle stake to Angelini Pharma

Jan 04

Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

Dec 24
Here's Why We're Watching Sio Gene Therapies' (NASDAQ:SIOX) Cash Burn Situation

Sio Gene Therapies soars 45% on positive AXO-AAV-GM1 data in nerve cell disorder

Dec 16

Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

Nov 19
Did Sio Gene Therapies, Inc. (NASDAQ:SIOX) Insiders Buy Up More Shares?

Axovant on go with pivotal study of gene therapy for rare inherited lipid disorders

Nov 09

Axovant sees delayed enrollment in Parkinson’s study with gene therapy

Oct 29

Analyse CEO-vergoeding

Hoe is David Nassif's beloning veranderd ten opzichte van Sio Gene Therapies's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2022n/an/a

-US$29m

Sep 30 2022n/an/a

-US$50m

Jun 30 2022n/an/a

-US$68m

Mar 31 2022US$2mUS$454k

-US$72m

Dec 31 2021n/an/a

-US$62m

Sep 30 2021n/an/a

-US$47m

Jun 30 2021n/an/a

-US$36m

Mar 31 2021US$1mUS$414k

-US$32m

Dec 31 2020n/an/a

-US$46m

Sep 30 2020n/an/a

-US$49m

Jun 30 2020n/an/a

-US$53m

Mar 31 2020US$2mUS$300k

-US$73m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van David redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de US markt.

Compensatie versus inkomsten: De vergoeding van David is gestegen terwijl het bedrijf verliesgevend is.


CEO

David Nassif (69 yo)

4.6yrs

Tenure

US$1,617,173

Compensatie

Mr. David W. Nassif, J.D., serves as Chief Executive Officer of Sio Gene Therapies Inc. since May 2022 and also serves as its General Counsel since July 01, 2019 and serves as its Chief Financial Officer....